Siemens Healthineers announced that it agreed to expand its strategic collaboration with Mayo Clinic to enhance patient care.
The organizations aim to enhance care for neurodegenerative disease and the management of prostate cancer and metastatic liver tumors. Their agreement intends to improve care for those disease states and expand access to new imaging and interventional technologies.
Included in the collaboration is the initial goal to improve care for neurodegenerative disease. Siemens Healthineers and Mayo Clinic hope to advance AI-enabled MRI protocols for improved diagnostic accuracy and patient monitoring.
Additionally, they hope to apply digital twin technology to re-imagine how patients experience surgery. This enhances the experience and improves operational efficiency along the surgical care pathway. For prostate cancer, they plan to jointly investigate the role of AI in minimizing biopsies and the integration of minimally invasive, advanced imaging into diagnostic and therapeutic procedures.
Siemens Healthineers said they hope to deliver clinical translation for image-guided technologies, delivering precise detection and treatment for liver metastases. With Mayo Clinic, it hopes to drive the clinical adoption and translation of ultra-high-field MRI protocols. This takes advantage of the technology’s high resolution and enhanced contrast for diagnostic and surgical planning in complex neurological disease states.
The organizations also plan for an innovation center for whole-body PET/CT and PET/MR imaging. This would emphasize theranostics treatment for certain cancers and simultaneous anatomical and metabolic MR imaging.
Leading imaging technology developers continue to work with Mayo Clinic on collaborations like this. GE HealthCare inked a deal with Mayo Clinic centered around cancer care in December 2025.
Commentary from Siemens Healthineers and Mayo Clinic officials
John Kowal, president and head of the Americas at Siemens Healthineers, said:
“Improving the diagnosis and treatment of neurodegenerative disease and cancer is core to our purpose as a company. Our collaboration with Mayo Clinic creates significant opportunities to help extend the quantity and quality of patients’ lives.”
Dr. Eric Williamson, professor and chair, diagnostic radiology, Mayo Clinic, said:
“Our goal is to make care more precise, less invasive, and more responsive to each patient’s needs. By expanding our collaboration, we can bring advanced imaging, artificial intelligence, and innovative treatment approaches directly into everyday clinical care, potentially helping patients receive earlier diagnoses, more personalized treatment plans, and better outcomes.”
